Insulin-like growth factor system in growth, development and carcinogenesis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

IGF-I and IGF-II are polypeptides with significant homology to proinsulin that exert growth-regulatory and differentiation effects on several cell types throughout the life span of animals. At least three receptors (R), IGF-I-R, IGF-II-R and insulin R (IR) mediate biological effects of insulin-like growth factors (IGFs). IGFs are potentially available to the cells via autocrine, endocrine, and paracrine pathways, making them some of the most available growth factors in the microenvironment of cells. IGF-I-R and IR are tyrosine kinase receptors and mediate growth and metabolic effects of IGFs. IGF-II-R preferentially bind IGF-II, followed by internalization and degradation of the peptide. Biological effects of IGF-II are thus dictated by stoichiometric expression of IGF-I-R vs IGF-II-R. IGF binding proteins (BP-1-6) have a high binding affinity for IGFs and regulate their bio-efficacy. Regulatory function of BPs is further modulated by IGFBP proteinases and "receptor-like" proteins that bind BPs, resulting in IGF independent effects of BPs. The availability of BPs, as either intact, bound, or proteolytic forms, can significantly modulate the final biological action of IGFs. Thus, the IGF system includes IGFs, IGF receptors, IGFBPs, IGFBP proteinases, and IGFBP-binding proteins (receptors?). IGFs are being increasingly recognized as a major regulatory force in health and disease by cancer biologists, endocrinologists, neuroscientists, and physiologists and are currently being used for diagnostic, prognostic, and therapeutic purposes. In this review, we will outline recent developments in this field with an emphasis on cancer.

Original languageEnglish (US)
Pages (from-to)214-232
Number of pages19
JournalJournal of Clinical Ligand Assay
Volume23
Issue number3
StatePublished - 2000

Fingerprint

Somatomedins
Growth and Development
Carcinogenesis
Insulin-Like Growth Factor II
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Peptide Hydrolases
Insulin
Somatomedin Receptors
Cellular Microenvironment
Insulin-Like Growth Factor Binding Protein 1
Proinsulin
IGF Type 1 Receptor
Peptides
Receptor Protein-Tyrosine Kinases
Growth
Neoplasms
Intercellular Signaling Peptides and Proteins
Carrier Proteins
Animals

Keywords

  • Breast cancer
  • Colon cancer
  • IGF-I-receptors
  • IGFBPs
  • IGFs
  • Prostate cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology

Cite this

Insulin-like growth factor system in growth, development and carcinogenesis. / Singh, Pomila.

In: Journal of Clinical Ligand Assay, Vol. 23, No. 3, 2000, p. 214-232.

Research output: Contribution to journalArticle

@article{fbdf40f2a2c24ae1be07f86a948e574b,
title = "Insulin-like growth factor system in growth, development and carcinogenesis",
abstract = "IGF-I and IGF-II are polypeptides with significant homology to proinsulin that exert growth-regulatory and differentiation effects on several cell types throughout the life span of animals. At least three receptors (R), IGF-I-R, IGF-II-R and insulin R (IR) mediate biological effects of insulin-like growth factors (IGFs). IGFs are potentially available to the cells via autocrine, endocrine, and paracrine pathways, making them some of the most available growth factors in the microenvironment of cells. IGF-I-R and IR are tyrosine kinase receptors and mediate growth and metabolic effects of IGFs. IGF-II-R preferentially bind IGF-II, followed by internalization and degradation of the peptide. Biological effects of IGF-II are thus dictated by stoichiometric expression of IGF-I-R vs IGF-II-R. IGF binding proteins (BP-1-6) have a high binding affinity for IGFs and regulate their bio-efficacy. Regulatory function of BPs is further modulated by IGFBP proteinases and {"}receptor-like{"} proteins that bind BPs, resulting in IGF independent effects of BPs. The availability of BPs, as either intact, bound, or proteolytic forms, can significantly modulate the final biological action of IGFs. Thus, the IGF system includes IGFs, IGF receptors, IGFBPs, IGFBP proteinases, and IGFBP-binding proteins (receptors?). IGFs are being increasingly recognized as a major regulatory force in health and disease by cancer biologists, endocrinologists, neuroscientists, and physiologists and are currently being used for diagnostic, prognostic, and therapeutic purposes. In this review, we will outline recent developments in this field with an emphasis on cancer.",
keywords = "Breast cancer, Colon cancer, IGF-I-receptors, IGFBPs, IGFs, Prostate cancer",
author = "Pomila Singh",
year = "2000",
language = "English (US)",
volume = "23",
pages = "214--232",
journal = "Journal of Clinical Ligand Assay",
issn = "1081-1672",
publisher = "Clinical Ligand Assay Society Inc.",
number = "3",

}

TY - JOUR

T1 - Insulin-like growth factor system in growth, development and carcinogenesis

AU - Singh, Pomila

PY - 2000

Y1 - 2000

N2 - IGF-I and IGF-II are polypeptides with significant homology to proinsulin that exert growth-regulatory and differentiation effects on several cell types throughout the life span of animals. At least three receptors (R), IGF-I-R, IGF-II-R and insulin R (IR) mediate biological effects of insulin-like growth factors (IGFs). IGFs are potentially available to the cells via autocrine, endocrine, and paracrine pathways, making them some of the most available growth factors in the microenvironment of cells. IGF-I-R and IR are tyrosine kinase receptors and mediate growth and metabolic effects of IGFs. IGF-II-R preferentially bind IGF-II, followed by internalization and degradation of the peptide. Biological effects of IGF-II are thus dictated by stoichiometric expression of IGF-I-R vs IGF-II-R. IGF binding proteins (BP-1-6) have a high binding affinity for IGFs and regulate their bio-efficacy. Regulatory function of BPs is further modulated by IGFBP proteinases and "receptor-like" proteins that bind BPs, resulting in IGF independent effects of BPs. The availability of BPs, as either intact, bound, or proteolytic forms, can significantly modulate the final biological action of IGFs. Thus, the IGF system includes IGFs, IGF receptors, IGFBPs, IGFBP proteinases, and IGFBP-binding proteins (receptors?). IGFs are being increasingly recognized as a major regulatory force in health and disease by cancer biologists, endocrinologists, neuroscientists, and physiologists and are currently being used for diagnostic, prognostic, and therapeutic purposes. In this review, we will outline recent developments in this field with an emphasis on cancer.

AB - IGF-I and IGF-II are polypeptides with significant homology to proinsulin that exert growth-regulatory and differentiation effects on several cell types throughout the life span of animals. At least three receptors (R), IGF-I-R, IGF-II-R and insulin R (IR) mediate biological effects of insulin-like growth factors (IGFs). IGFs are potentially available to the cells via autocrine, endocrine, and paracrine pathways, making them some of the most available growth factors in the microenvironment of cells. IGF-I-R and IR are tyrosine kinase receptors and mediate growth and metabolic effects of IGFs. IGF-II-R preferentially bind IGF-II, followed by internalization and degradation of the peptide. Biological effects of IGF-II are thus dictated by stoichiometric expression of IGF-I-R vs IGF-II-R. IGF binding proteins (BP-1-6) have a high binding affinity for IGFs and regulate their bio-efficacy. Regulatory function of BPs is further modulated by IGFBP proteinases and "receptor-like" proteins that bind BPs, resulting in IGF independent effects of BPs. The availability of BPs, as either intact, bound, or proteolytic forms, can significantly modulate the final biological action of IGFs. Thus, the IGF system includes IGFs, IGF receptors, IGFBPs, IGFBP proteinases, and IGFBP-binding proteins (receptors?). IGFs are being increasingly recognized as a major regulatory force in health and disease by cancer biologists, endocrinologists, neuroscientists, and physiologists and are currently being used for diagnostic, prognostic, and therapeutic purposes. In this review, we will outline recent developments in this field with an emphasis on cancer.

KW - Breast cancer

KW - Colon cancer

KW - IGF-I-receptors

KW - IGFBPs

KW - IGFs

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0034495366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034495366&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034495366

VL - 23

SP - 214

EP - 232

JO - Journal of Clinical Ligand Assay

JF - Journal of Clinical Ligand Assay

SN - 1081-1672

IS - 3

ER -